Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals Inc (ORMP)
:ORMP
Top Page
Oramed Pharm
(NASDAQ:ORMP)
47Neutral
Positive Factors
Investment
The joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint Venture
Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Negative Factors
Clinical Efficacy
The candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
Oramed Pharm (ORMP) vs. S&P 500 (SPY)
Market Cap
$90.28M
Dividend YieldN/A
Average Volume (3M)140.75K
Price to Earnings (P/E)21.1
Beta (1Y)1.09
Revenue Growth-100.00%
EPS GrowthN/A
CountryUS
Employees13
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding40,850,456
10 Day Avg. Volume37,260
30 Day Avg. Volume140,751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)70.09
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oramed Pharm Business Overview & Revenue Model
Company DescriptionOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
How the Company Makes MoneyOramed Pharmaceuticals generates revenue primarily through the development and potential commercialization of its oral drug delivery technology. The company's revenue model is heavily reliant on successful clinical trials and the subsequent approval and licensing of its products. Oramed partners with pharmaceutical companies to co-develop and license its technologies, receiving milestone payments and royalties from these collaborations. Additionally, the company may engage in research and development service agreements, contributing to its revenue streams. However, as a clinical-stage company, its current earnings are mostly derived from partnerships and investments aimed at advancing its clinical programs.
Oramed Pharm Financial Statement Overview
Summary
Oramed Pharm's financial performance is mixed. The income statement is weak due to zero revenue and negative EBIT, while the balance sheet is strong with a high equity ratio. Cash flow is negative, indicating liquidity issues.Income Statement
Oramed Pharm's income statement reflects significant challenges, primarily due to zero revenue in the TTM, a negative EBIT, and fluctuating net income figures. The lack of revenue growth and negative margins highlight ongoing operational inefficiencies.25
Negative
Balance Sheet
The balance sheet shows a strong equity position with a high equity ratio, indicative of financial stability. However, the debt-to-equity ratio is low, providing some leverage risk, but overall liabilities remain manageable relative to equity.55
Neutral
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, indicating potential liquidity issues. The operating cash flow to net income ratio is unfavorable, suggesting challenges in converting income into cash flow.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 1.34M | 2.70M | 2.70M | 2.71M | 2.70M |
| Gross Profit | |||||
| 0.00 | 1.34M | 2.70M | 2.70M | 2.62M | 2.61M |
| EBIT | |||||
| -13.06M | -15.77M | -40.60M | -24.22M | -11.76M | -14.63M |
| EBITDA | |||||
| 24.86M | -15.57M | -36.98M | -25.04M | -11.31M | -14.17M |
| Net Income Common Stockholders | |||||
| 4.46M | 5.53M | -37.76M | -22.24M | -11.51M | -14.36M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.34M | 162.05M | 155.72M | 94.14M | 39.90M | 32.28M |
| Total Assets | |||||
| 5.96M | 220.55M | 161.64M | 128.00M | 44.63M | 34.66M |
| Total Debt | |||||
| 0.00 | 51.62M | 894.00K | 533.00K | 75.00K | 0.00 |
| Net Debt | |||||
| -2.04M | 42.57M | -39.57M | -76.71M | -19.22M | -3.33M |
| Total Liabilities | |||||
| 709.29K | 57.66M | 10.49M | 11.48M | 11.75M | 15.27M |
| Stockholders Equity | |||||
| 5.25M | 163.82M | 151.81M | 115.77M | 32.88M | 19.39M |
| Cash Flow | Free Cash Flow | ||||
| -7.93M | -10.55M | -28.41M | -21.56M | -12.52M | -12.96M |
| Operating Cash Flow | |||||
| -7.92M | -10.29M | -27.92M | -21.18M | -12.44M | -12.94M |
| Investing Cash Flow | |||||
| 120.39M | -73.04M | 30.21M | -23.76M | 4.63M | 11.26M |
| Financing Cash Flow | |||||
| -75.84M | 51.98M | 10.78M | 102.89M | 23.79M | 0.00 |
Oramed Pharm Technical Analysis
Negative
2.21
Price Trends
2.30
Negative
2.34
Negative
2.37
Negative
Market Momentum
<0.01
Positive
41.96
Neutral
16.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Negative. The current price of 2.21 is below the 20-day moving average (MA) of 2.35, below the 50-day MA of 2.30, and below the 200-day MA of 2.37, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.96 is Neutral, neither overbought nor oversold. The STOCH value of 16.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORMP.
Oramed Pharm Risk Analysis
Oramed Pharm disclosed 45 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oramed Pharm Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $2.07B | 48.01 | -0.53% | ― | 27.28% | -101.63% | |
58 Neutral | $1.53B | 54.97 | -35.00% | ― | 43.50% | ― | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
47 Neutral | $90.28M | 21.10 | -12.29% | ― | -100.00% | ― | |
47 Neutral | $318.70M | ― | -526.33% | ― | ― | 14.39% | |
42 Neutral | $181.18M | ― | -15.79% | ― | -25.86% | -37.14% | |
41 Neutral | $3.56M | ― | 1155.92% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
ORMP
Oramed Pharm
2.21
-0.62
-21.91%
AMRN
Amarin
0.44
-0.44
-50.00%
LGND
Ligand Pharma
107.62
34.02
46.22%
MNKD
MannKind
5.03
0.69
15.90%
VSTM
Verastem
6.19
-5.54
-47.23%
RDHL
RedHill Biopharma
2.79
-10.95
-79.69%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.